- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06113744
A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine
A Randomised, Blinded, Parallel-controlled Phase 1 Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of a COVID-19 mRNA Vaccine in Healthy Adult Subjects
Study Overview
Status
Conditions
Detailed Description
The phase 1 clinical trial is conducted in a randomised, blinded, parallel-controlled design to assess the safety, immunogenicity and immune persistence. Subjects will be divided into two age groups (18-59 and ≧60 years of age), and within the groups, subjects will be subdivided into three dose groups (10 μg,30 μg and 60 μg). The immunisation procedure is divided into one-dose group and two-dose group (0, 28 days).
The total sample size is 164 subjects. 12 subjects will be assigned to each group according to different age, dose and immunisation procedure, respectively. In addition, 20 subjects (10 aged 18-59 years and 10 aged ≧60 years) will be enrolled as active control and vaccinated with 2 doses of inactivated Covid vaccine (Vero cell) (0, 28 days).
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Guiling Chen
- Phone Number: 86-18343113983
- Email: chenguiling707@126.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Recruiting
- Shulan (Hangzhou) hospital
-
Contact:
- Guiling Chen
- Phone Number: 86-18343113983
- Email: chenguiling707@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy male or female subjects aged ≥18 years of age;
- Subjects who are in good physical condition as judged by the investigator based on medical history, physical examination and clinical laboratory tests;
- Subjects who have not been previously vaccinated with a Covid-19 vaccine or who have received the last dose (total dose ≤ 3 doses) of a Covid-19 vaccine at least 6 months ago;
- Subjects who have not been previously infected with Covid-19, or whose nucleic acid or antigen test has turned negative for more than 1 month after previous Covid-19 infection;
- Subjects who have used effective contraception since 2 weeks prior to enrolment;
- Subjects or their delegates are able to understand the study procedures, have provide written informed consent, and are able to comply with the requirements of the clinical study protocol.
Exclusion Criteria:
- Females of childbearing potential who have a positive pregnancy test, are pregnant, breastfeeding, or planning to become pregnant within 12 months; males: whose spouse is planning to become pregnant within 1 year;
- History of epilepsy, convulsions or seizures, psychosis or family history of psychosis;
- Subjects who were using antipyretic, analgesic or anti-allergic drugs within 3 days before enrolment;
- Have a previous history of severe allergy to any medication or vaccination (e.g. acute allergic reaction, urticaria, skin eczema, dyspnoea, angioneurotic oedema, or abdominal pain) or allergy to known components of a Covid-19 vaccine;
- Have a history of hospital-diagnosed thrombocytopenia or other coagulation disorders;
- Have a history of hospital-diagnosed known immunological impairment or hypofunction;
- Subjects who have received immunoenhancement or immunosuppressant therapy (continuous use by oral or infusion for more than 14 days) within 3 months, and whole blood, plasma, or immunoglobulin within 1 month;
- Known or suspected concomitant serious diseases, including: respiratory diseases, acute infections or active chronic diseases, liver and kidney diseases, severe diabetes, malignant tumours, infectious or allergic skin diseases, cardiovascular disease, and HIV infection (with test report);
- Subjects suffering from various acute diseases or in the acute exacerbation of chronic diseases within 3 days before vaccination;
- Subjects with clinically significant abnormalities in blood biochemistry, blood routine, urine routine, coagulation function, thyroid function, and myocarditis-related indicators detected during the screening;
- Received live attenuated vaccine within 1 month before vaccination;
- Received inactivated vaccine within 14 days before vaccination;
- Axillary temperature ≥37.3℃;
- Who have participated in other clinical trials within 3 months prior to the first dose of vaccination or plan to participate in other clinical trials during the study period;
- Other conditions that the investigator deems inappropriate for participation in this clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low-dose test vaccine, 1 dose
|
Low-dose
|
Experimental: Mid-dose test vaccine, 1 dose
|
Mid-dose
|
Experimental: High-dose test vaccine, 1 dose
|
High-dose
|
Placebo Comparator: Placebo, 1 dose
|
saline
|
Experimental: Low-dose test vaccine, 2 dose
|
Low-dose
|
Experimental: Mid-dose test vaccine, 2 dose
|
Mid-dose
|
Experimental: High-dose test vaccine, 2 dose
|
High-dose
|
Placebo Comparator: Placebo, 2 doses
|
saline
|
Active Comparator: Active control vaccine, 2 doses
|
COVILO
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and frequency of adverse event (AE)
Time Frame: Day 0~Day 28 after each dose of vaccination
|
Incidence of local/systemic adverse reactions/events 0-14 days and 15-28 days after each dose of vaccination, and incidence of solicited adverse events within 14 days after each dose of vaccination
|
Day 0~Day 28 after each dose of vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cross-neutralisation against different SARS-CoV-2 variants
Time Frame: From the first dose of immunisation to 28 days after full immunisation
|
The cross-neutralization effect of the mRNA vaccine (Omicron strain) against different SARS-CoV-2 variants (ancestral strain, Omicron strain and main circulating strain)
|
From the first dose of immunisation to 28 days after full immunisation
|
4-fold increasing rate, GMT and GMI of NAbs against SARS-CoV-2 on 90, 180 and 360 days after full immunisation
Time Frame: Day 90~Day 360 after full immunisation
|
4-fold increasing rate, GMT and GMI of NAbs against SARS-CoV-2 on 90, 180 and 360 days after full immunisation
|
Day 90~Day 360 after full immunisation
|
Number and frequency of serious adverse event (SAE)
Time Frame: From the first dose of immunisation to 12 months after full immunisation
|
Incidence of SAE from the first dose up to 12 months after full immunisation
|
From the first dose of immunisation to 12 months after full immunisation
|
4-fold increasing rate, geometric mean titre (GMT) and geometric mean increase (GMI) of neutralizing antibodies (Nabs) against SARS-CoV-2 on 14 days and 28 days after full immunisation
Time Frame: From the first dose of immunisation to 28 days after full immunisation
|
4-fold increasing rate, GMT and GMI of neutralizing antibody (Nabs) against SARS-CoV-2 on 14 days and 28 days after full immunisation
|
From the first dose of immunisation to 28 days after full immunisation
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in cytokine levels in Th1/Th2 cells induced by S protein
Time Frame: From before the first dose of immunisation to 28 days after full immunisation
|
Cytokine (IFN-γ, IL-4, IL-2) levels in Th1/Th2 cells changed from pre-dose to 28 days after the full immunisation
|
From before the first dose of immunisation to 28 days after full immunisation
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Yunkai Yang, China National Biotec Group Company Limited
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZSVG-02-O-2022-P1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-CoV-2 Infection
-
St. Olavs HospitalThe Research Council of Norway; Helse Nord-Trøndelag HF; Alesund Hospital; Namsos... and other collaboratorsCompletedSARS-CoV-2 Acute Respiratory Disease | SARS-CoV-2 Sepsis | SARS CoV 2 InfectionNorway
-
Boston UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Burnet Institute and other collaboratorsRecruitingSARS CoV 2 Infection | SARS CoV 2 VaccinationUnited States, Malawi
-
Argorna Pharmaceuticals Co., LTDCompleted
-
Argorna Pharmaceuticals Co., LTDCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Active, not recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Active, not recruiting
-
Arcturus Therapeutics, Inc.Terminated
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsCompleted
-
Centre Hospitalier Universitaire DijonUnknown
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and PreventionNot yet recruiting
Clinical Trials on COVID-19 Vaccine (Vero Cell) ,Inactivated
-
China National Biotec Group Company LimitedThe University of Hong Kong; Beijing Institute of Biological Products Co Ltd.; Wuhan Institute of Biological Products Co., LtdActive, not recruiting
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.; Hunan Provincial Center for...Active, not recruiting
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.Active, not recruiting
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.; Shulan (Hangzhou) HospitalActive, not recruiting
-
Sinovac Biotech (Colombia) S.A.S.Sinovac Life Sciences Co., Ltd.Not yet recruiting
-
Sinovac Research and Development Co., Ltd.Active, not recruiting
-
Sinovac Research and Development Co., Ltd.Recruiting
-
WestVac Biopharma Co., Ltd.West China HospitalCompletedCOVID-19 | SARS-CoV-2 InfectionChina
-
WestVac Biopharma Co., Ltd.Active, not recruitingCOVID-19 | SARS-CoV-2 InfectionMexico
-
WestVac Biopharma Co., Ltd.CompletedCOVID-19 | SARS-CoV-2 InfectionPhilippines